Objective: Major depression (MD) is a condition associated with both hepatitis C virus (HCV) infection and pegylated interferon (IFN)-α treatment. IFN induces a depressive syndrome that is associated with an inflammatory profile. We aimed to investigate whether there is any specific alteration in plasma biomarkers associated with MD. Methods: HCV-monoinfected patients, with and without IFN treatment, were followed up for 18 months and went through structured psychiatric evaluation. We assessed plasma levels of brain-derived neurotrophic factor, tumor necrosis factor (TNF) and its soluble type 1 and type 2 receptors (sTNFR1 and sTNFR2, respectively), and adipokines (adiponectin, leptin and resistin) using ELISA. Results: Among the 50 patients included in the study, 14 were treated with IFN during the follow-up. Being older, not married, presenting higher body mass index, higher liver inflammatory activity, lower baseline adiponectin levels and use of IFN were associated with MD development. Higher levels of sTNFR1 during IFN treatment were associated with sustained virological response. The lack of a control group without HCV infection did not allow any assumption of a biomarker change exclusively due to the infection itself. Conclusion: Adiponectin may be a resilience biomarker for MD in HCV-infected patients.

1.
Lavanchy D: Evolving epidemiology of hepatitis C virus. Clin Microbiol Infect 2011;17:107-115.
2.
Mohd Hanafiah K, Groeger J, Flaxman AD, Wiersma ST: Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence. Hepatology 2013;57:1333-1342.
3.
Feld JJ: The beginning of the end: what is the future of interferon therapy for chronic hepatitis C? Antiviral Res 2014;105:32-38.
4.
Marcellin P, Lau GK, Zeuzem S, Heathcote EJ, Pockros PJ, Reddy KR, et al: Comparing the safety, tolerability and quality of life in patients with chronic hepatitis B vs chronic hepatitis C treated with peginterferon alpha-2a. Liver Int 2008;28:477-485.
5.
Carta MG, Hardoy MC, Garofalo A, Pisano E, Nonnoi V, Intilla G, et al: Association of chronic hepatitis C with major depressive disorders: irrespective of interferon-alpha therapy. Clin Pract Epidemiol Ment Health 2007;3:22.
6.
Fábregas BC, de Ávila RE, Faria MN, Moura AS, Carmo RA, Teixeira AL: Health related quality of life among patients with chronic hepatitis C: a cross-sectional study of sociodemographic, psychopathological and psychiatric determinants. Braz J Infect Dis 2013;17:633-639.
7.
Schaefer M, Capuron L, Friebe A, Diez-Quevedo C, Robaeys G, Neri S, et al: Hepatitis C infection, antiviral treatment and mental health: a European expert consensus statement. J Hepatol 2012;57:1379-1390.
8.
Fletcher NF, Wilson GK, Murray J, Hu K, Lewis A, Reynolds GM, et al: Hepatitis C virus infects the endothelial cells of the blood-brain barrier. Gastroenterology 2012;142:634.e6-643.e6.
9.
Wilkinson J, Radkowski M, Eschbacher JM, Laskus T: Activation of brain macrophages/microglia cells in hepatitis C infection. Gut 2010;59:1394-1400.
10.
Raison CL, Capuron L, Miller AH: Cytokines sing the blues: inflammation and the pathogenesis of depression. Trends Immunol 2006;27:24-31.
11.
Huckans M, Fuller BE, Olavarria H, Sasaki AW, Chang M, Flora KD, et al: Multi-analyte profile analysis of plasma immune proteins: altered expression of peripheral immune factors is associated with neuropsychiatric symptom severity in adults with and without chronic hepatitis C virus infection. Brain Behav 2014;4:123-142.
12.
Lotrich FE, Albusaysi S, Ferrell RE: Brain-derived neurotrophic factor serum levels and genotype: association with depression during interferon-α treatment. Neuropsychopharmacology 2013;38:985-995.
13.
Ouchi N, Parker JL, Lugus JJ, Walsh K: Adipokines in inflammation and metabolic disease. Nat Rev Immunol 2011;11:85-97.
14.
Wilhelm CJ, Choi D, Huckans M, Manthe L, Loftis JM: Adipocytokine signaling is altered in Flinders sensitive line rats, and adiponectin correlates in humans with some symptoms of depression. Pharmacol Biochem Behav 2013;103:643-651.
15.
Jeong HG, Min BJ, Lim S, Kim TH, Lee JJ, Park JH, et al: Plasma adiponectin elevation in elderly individuals with subsyndromal depression. Psychoneuroendocrinology 2012;37:948-955.
16.
Silva TE, Colombo G, Schiavon LL: Adiponectin: a multitasking player in the field of liver diseases. Diabetes Metab 2014;40:95-107.
17.
Fábregas BC, Vitorino FD, Rocha DM, Moura AS, Carmo RA, Teixeira AL: Screening inventories to detect depression in chronic hepatitis C patients. Gen Hosp Psychiatry 2012;34:40-45.
18.
Fábregas BC, Abreu MN, Dos Santos AK, Moura AS, Carmo RA, Teixeira AL: Impulsiveness in chronic hepatitis C patients. Gen Hosp Psychiatry 2014;36:261-265.
19.
Folstein MF, Folstein SE, McHugh PR: ‘Mini-Mental State'. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189-198.
20.
Sheehan DV, Lecrubier Y, Sheehan KH, Amorim P, Janavs J, Weiller E, et al: The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry 1998;59(suppl 20):22-33.
21.
Amorim P: Mini International Neuropsychiatric Interview (MINI): validação de entrevista breve para diagnóstico de transtornos mentais. Rev Bras Psiquiatr 2000;22:106-115.
22.
Beck AT, Ward CH, Mendelson M, Mock J, Erbaugh J: An inventory for measuring depression. Arch Gen Psychiatry 1961;4:561-571.
23.
Zigmond AS, Snaith RP: The hospital anxiety and depression scale. Acta Psychiatr Scand 1983;67:361-370.
24.
Hamilton M: A rating scale for depression. J Neurol Neurosurg Psychiatry 1960;23:56-62.
25.
Hamilton M: The assessment of anxiety states by rating. Br J Med Psychol 1959;32:50-55.
26.
Mendoza TR, Wang XS, Cleeland CS, Morrissey M, Johnson BA, Wendt JK, et al: The rapid assessment of fatigue severity in cancer patients: use of the Brief Fatigue Inventory. Cancer 1999;85:1186-1196.
27.
Kramer MS, Lydon J, Séguin L, Goulet L, Kahn SR, McNamara H, et al: Stress pathways to spontaneous preterm birth: the role of stressors, psychological distress, and stress hormones. Am J Epidemiol 2009;169:1319-1326.
28.
Patton JH, Stanford MS, Barratt ES: Factor structure of the Barratt Impulsiveness Scale. J Clin Psychol 1995;51:768-774.
29.
von Diemen L, Szobot CM, Kessler F, Pechansky F: Adaptation and construct validation of the Barratt Impulsiveness Scale (BIS 11) to Brazilian Portuguese for use in adolescents. Rev Bras Psiquiatr 2007;29:153-156.
30.
Skevington SM, McCrate FM: Expecting a good quality of life in health: assessing people with diverse diseases and conditions using the WHOQOL-BREF. Health Expect 2012;15:49-62.
31.
Liang WM, Chang CH, Yeh YC, Shy HY, Chen HW, Lin MR: Psychometric evaluation of the WHOQOL-BREF in community-dwelling older people in Taiwan using Rasch analysis. Qual Life Res 2009;18:605-618.
32.
Fleck MP, Louzada S, Xavier M, Chachamovich E, Vieira G, Santos L, et al: Application of the Portuguese version of the instrument for the assessment of quality of life of the World Health Organization (WHOQOL-100) (in Portuguese). Rev Saude Publica 1999;33:198-205.
33.
Fleck MP, Louzada S, Xavier M, Chachamovich E, Vieira G, Santos L, et al: Application of the Portuguese version of the abbreviated instrument of quality life WHOQOL-bref (in Portuguese). Rev Saude Publica 2000;34:178-183.
34.
Ogawa E, Furusyo N, Kajiwara E, Takahashi K, Nomura H, Tanabe Y, et al: Evaluation of the adverse effect of premature discontinuation of pegylated interferon α-2b and ribavirin treatment for chronic hepatitis C virus infection: results from Kyushu University Liver Disease Study. J Gastroenterol Hepatol 2012;27:1233-1240.
35.
Volkert J, Schulz H, Härter M, Wlodarczyk O, Andreas S: The prevalence of mental disorders in older people in Western countries - a meta-analysis. Ageing Res Rev 2013;12:339-353.
36.
Hoyo-Becerra C, Schlaak JF, Hermann DM: Insights from interferon-α-related depression for the pathogenesis of depression associated with inflammation. Brain Behav Immun 2014;42:222-231.
37.
Franceschi C, Bonafè M, Valensin S, Olivieri F, De Luca M, Ottaviani E, et al: Inflamm-aging. An evolutionary perspective on immunosenescence. Ann NY Acad Sci 2000;908:244-254.
38.
Zhou X, Yan Z, Hesketh T, Therese H: Depression and aggression in never-married men in China: a growing problem. Soc Psychiatry Psychiatr Epidemiol 2013;48:1087-1093.
39.
Breslau J, Miller E, Jin R, Sampson NA, Alonso J, Andrade LH, et al: A multinational study of mental disorders, marriage, and divorce. Acta Psychiatr Scand 2011;124:474-486.
40.
Luppino FS, de Wit LM, Bouvy PF, Stijnen T, Cuijpers P, Penninx BW, et al: Overweight, obesity, and depression: a systematic review and meta-analysis of longitudinal studies. Arch Gen Psychiatry 2010;67:220-229.
41.
Makki K, Froguel P, Wolowczuk I: Adipose tissue in obesity-related inflammation and insulin resistance: cells, cytokines, and chemokines. ISRN Inflamm 2013;2013:139239.
42.
Jung UJ, Choi MS: Obesity and its metabolic complications: the role of adipokines and the relationship between obesity, inflammation, insulin resistance, dyslipidemia and nonalcoholic fatty liver disease. Int J Mol Sci 2014;15:6184-6223.
43.
Yildiz BO, Suchard MA, Wong ML, McCann SM, Licinio J: Alterations in the dynamics of circulating ghrelin, adiponectin, and leptin in human obesity. Proc Natl Acad Sci USA 2004;101:10434-10439.
44.
Saxena NK, Fu PP, Nagalingam A, Wang J, Handy J, Cohen C, et al: Adiponectin modulates C-jun N-terminal kinase and mammalian target of rapamycin and inhibits hepatocellular carcinoma. Gastroenterology 2010;139:1762-1773, 1773.e1-1773.e5.
45.
Sun B, Karin M: Obesity, inflammation, and liver cancer. J Hepatol 2012;56:704-713.
46.
Wędrychowicz A, Zając A, Pilecki M, Kościelniak B, Tomasik PJ: Peptides from adipose tissue in mental disorders. World J Psychiatry 2014;4:103-111.
47.
Cizza G, Nguyen VT, Eskandari F, Duan Z, Wright EC, Reynolds JC, et al: Low 24-hour adiponectin and high nocturnal leptin concentrations in a case-control study of community-dwelling premenopausal women with major depressive disorder: the Premenopausal, Osteopenia/Osteoporosis, Women, Alendronate, Depression (POWER) study. J Clin Psychiatry 2010;71:1079-1087.
48.
Zeman M, Jirak R, Jachymova M, Vecka M, Tvrzicka E, Zak A: Leptin, adiponectin, leptin to adiponectin ratio and insulin resistance in depressive women. Neuro Endocrinol Lett 2009;30:387-395.
49.
Carvalho AF, Rocha DQ, McIntyre RS, Mesquita LM, Köhler CA, Hyphantis TN, et al: Adipokines as emerging depression biomarkers: a systematic review and meta-analysis. J Psychiatr Res 2014;59:28-37.
50.
Zhang D, Guo M, Zhang W, Lu XY: Adiponectin stimulates proliferation of adult hippocampal neural stem/progenitor cells through activation of p38 mitogen-activated protein kinase (p38MAPK)/glycogen synthase kinase 3β (GSK-3β)/β-catenin signaling cascade. J Biol Chem 2011;286:44913-44920.
51.
Snyder JS, Soumier A, Brewer M, Pickel J, Cameron HA: Adult hippocampal neurogenesis buffers stress responses and depressive behaviour. Nature 2011;476:458-461.
52.
Masi G, Brovedani P: The hippocampus, neurotrophic factors and depression: possible implications for the pharmacotherapy of depression. CNS Drugs 2011;25:913-931.
53.
Diniz BS, Teixeira AL, Talib LL, Mendonça VA, Gattaz WF, Forlenza OV: Increased soluble TNF receptor 2 in antidepressant-free patients with late-life depression. J Psychiatr Res 2010;44:917-920.
54.
Diniz BS, Teixeira AL, Campos AC, Miranda AS, Rocha NP, Talib LL, et al: Reduced serum levels of adiponectin in elderly patients with major depression. J Psychiatr Res 2012;46:1081-1085.
55.
Bougoulia M, Triantos A, Koliakos G: Effect of weight loss with or without orlistat treatment on adipocytokines, inflammation, and oxidative markers in obese women. Hormones (Athens) 2006;5:259-269.
56.
Palmer C, Hampartzoumian T, Lloyd A, Zekry A: A novel role for adiponectin in regulating the immune responses in chronic hepatitis C virus infection. Hepatology 2008;48:374-384.
57.
Bressler BL, Guindi M, Tomlinson G, Heathcote J: High body mass index is an independent risk factor for nonresponse to antiviral treatment in chronic hepatitis C. Hepatology 2003;38:639-644.
58.
Leandro G, Mangia A, Hui J, Fabris P, Rubbia-Brandt L, Colloredo G, et al: Relationship between steatosis, inflammation, and fibrosis in chronic hepatitis C: a meta-analysis of individual patient data. Gastroenterology 2006;130:1636-1642.
59.
Saad Y, Ahmed A, Saleh DA, Doss W: Adipokines and insulin resistance, predictors of response to therapy in Egyptian patients with chronic hepatitis C virus genotype 4. Eur J Gastroenterol Hepatol 2013;25:920-925.
60.
Udina M, Castellví P, Moreno-España J, Navinés R, Valdés M, Forns X, et al: Interferon-induced depression in chronic hepatitis C: a systematic review and meta-analysis. J Clin Psychiatry 2012;73:1128-1138.
61.
Su KP, Lai HC, Yang HT, Su WP, Peng CY, Chang JP, et al: Omega-3 fatty acids in the prevention of interferon-alpha-induced depression: results from a randomized, controlled trial. Biol Psychiatry 2014;76:559-566.
62.
Yamamoto T, Kajikawa Y, Otani S, Yamada Y, Takemoto S, Hirota M, et al: Protective effect of eicosapentaenoic acid on insulin resistance in hyperlipidemic patients and on the postoperative course of cardiac surgery patients: the possible involvement of adiponectin. Acta Med Okayama 2014;68:349-361.
63.
von Frankenberg AD, Silva FM, de Almeida JC, Piccoli V, do Nascimento FV, Sost MM, et al: Effect of dietary lipids on circulating adiponectin: a systematic review with meta-analysis of randomised controlled trials. Br J Nutr 2014;112:1235-1250.
64.
Baranyi A, Meinitzer A, Stepan A, Putz-Bankuti C, Breitenecker RJ, Stauber R, et al: A biopsychosocial model of interferon-alpha-induced depression in patients with chronic hepatitis C infection. Psychother Psychosom 2013;82:332-340.
65.
Sarkar S, Jiang Z, Evon DM, Wahed AS, Hoofnagle JH: Fatigue before, during and after antiviral therapy of chronic hepatitis C: results from the Virahep-C study. J Hepatol 2012;57:946-952.
66.
Wichers MC, Koek GH, Robaeys G, Verkerk R, Scharpé S, Maes M: IDO and interferon-alpha-induced depressive symptoms: a shift in hypothesis from tryptophan depletion to neurotoxicity. Mol Psychiatry 2005;10:538-544.
67.
Hiles SA, Baker AL, de Malmanche T, Attia J: A meta-analysis of differences in IL-6 and IL-10 between people with and without depression: exploring the causes of heterogeneity. Brain Behav Immun 2012;26:1180-1188.
68.
Liu Y, Ho RC, Mak A: Interleukin (IL)-6, tumour necrosis factor alpha (TNF-α) and soluble interleukin-2 receptors (sIL-2R) are elevated in patients with major depressive disorder: a meta-analysis and meta-regression. J Affect Disord 2012;139:230-239.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.